Cargando…
Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials
BACKGROUND: Recent studies have shown the efficacy for using spironolactone to treat heart failure with reduced ejection fraction (HFrEF), but the efficacy of spironolactone for heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) is uncl...
Autores principales: | Xiang, Yajie, Shi, Wenhai, Li, Zhuolin, Yang, Yunjing, Wang, Stephen Yishu, Xiang, Rui, Feng, Panpan, Wen, Li, Huang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456096/ https://www.ncbi.nlm.nih.gov/pubmed/30921200 http://dx.doi.org/10.1097/MD.0000000000014967 |
Ejemplares similares
-
Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
por: Enzan, Nobuyuki, et al.
Publicado: (2020) -
Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
por: Choy, Manting, et al.
Publicado: (2022) -
Heart rate in heart failure with mid-range ejection fraction
por: Yılmaz, Mehmet Birhan
Publicado: (2019) -
Epicardial fat in heart failure patients with mid‐range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2018) -
Heart Failure with Mid-Range Ejection Fraction - State of the
Art
por: Mesquita, Evandro Tinoco, et al.
Publicado: (2019)